"Substantia Nigra" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce DOPAMINE, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored MELANIN is a by-product of dopamine synthesis.
| Descriptor ID |
D013378
|
| MeSH Number(s) |
A08.186.211.132.659.413.656
|
| Concept/Terms |
Substantia Nigra- Substantia Nigra
- Nigra, Substantia
- Nigras, Substantia
- Substantia Nigras
|
Below are MeSH descriptors whose meaning is more general than "Substantia Nigra".
Below are MeSH descriptors whose meaning is more specific than "Substantia Nigra".
This graph shows the total number of publications written about "Substantia Nigra" by people in this website by year, and whether "Substantia Nigra" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 2 | 3 |
| 2002 | 4 | 0 | 4 |
| 2003 | 1 | 2 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 3 | 3 | 6 |
| 2007 | 4 | 2 | 6 |
| 2008 | 0 | 1 | 1 |
| 2009 | 4 | 3 | 7 |
| 2010 | 1 | 2 | 3 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 3 | 3 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 3 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 4 | 7 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Substantia Nigra" by people in Profiles.
-
Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs. Exp Neurol. 2023 10; 368:114509.
-
Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
-
A prebiotic diet modulates microglial states and motor deficits in a-synuclein overexpressing mice. Elife. 2022 11 08; 11.
-
Treadmill exercise reduces a-synuclein spreading via PPARa. Cell Rep. 2022 07 12; 40(2):111058.
-
Association of Lewy Bodies With Age-Related Clinical Characteristics in Black and White Decedents. Neurology. 2021 08 24; 97(8):e825-e835.
-
Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats. Drug Alcohol Depend. 2021 08 01; 225:108746.
-
Proteomic Profiling of the Substantia Nigra to Identify Determinants of Lewy Body Pathology and Dopaminergic Neuronal Loss. J Proteome Res. 2021 05 07; 20(5):2266-2282.
-
Reduction of Lewy Body Pathology by Oral Cinnamon. J Neuroimmune Pharmacol. 2021 09; 16(3):592-608.
-
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
-
Does Developmental Variability in the Number of Midbrain Dopamine Neurons Affect Individual Risk for Sporadic Parkinson's Disease? J Parkinsons Dis. 2020; 10(2):405-411.